AM240 MCR: new drug candidate currently being prepared for clinical studies

[Guest guest]

AnaMar Medical AB: AnaMar Medical Raises SEK 75 Million in New Financing

www.marketwatch.com/news/story/AnaMar-Medical-AB-AnaMar-Medical/story.aspx?guid=\

%7BC5D5CFE9-0ABC-4E27-A7BB-437B8BB13AB7%7D

STOCKHOLM, Sweden, Nov 06, 2008 (BUSINESS WIRE) -- The Swedish biotech

company AnaMar Medical raises SEK 75 millon in a rights issue to finance

continued development of its projects in chronic joint diseases. In a first

step, the funds will finance a phase I study of a drug candidate developed

for rheumatoid arthritis.

" We are happy to have successfully secured SEK 75 million in new financing

in the current financial climate. It's an acknowledgement that our principal

owner shares our confidence in our projects. With this financing in place,

we can take the first step into the clinic, " says AnaMar's CEO Owe GArlin.

" First in line is a compound that is being developed for rheumatoid

arthritis for which we will submit a Clinical Trials Application early next

year. Our next project is also approaching studies in man. "

The funds are provided through a rights issue guaranteed by AnaMar's

principal owner Koncentra Holding AB. All shareholders are invited to

participate in the rights issue.

The drug candidate that is currently being prepared for clinical studies is

developed in the project AM240 MCR and is an orally bioactive small molecule

compound that in preclinical studies has been shown to suppress inflammation

and cartilage destruction in disease models for rheumatoid arthritis. The

compound has also shown effect on pain.

The other project, AM260 TASS, is a compound that targets a receptor system

which is known to be involved in the immunomodulation process. The main

indication is treatment of rheumatoid arthritis. There are currently no

drugs on the market using the target receptor for the chosen indication.

AnaMar's focus is the identification and treatment of chronic joint disease,

in particular rheumatoid arthritis. The company was founded in 1998 to

commercialize research by the professors Dick HeinegArd and Tore Saxne at

the University in Lund, Sweden. Today, AnaMar has a broad portfolio of five

drug development projects and three biomarkers, originating from academic

institutions and selected partners.

AnaMar's largest owners are Koncentra Holding AB and LinkMed AB.

This information was brought to you by Cision http://www.cisionwire.com